


# MitraClip: Why, How, and For Whom?


Robert O. Bonow, MD, MS

Northwestern University Feinberg School of Medicine
Bluhm Cardiovascular Institute
Northwestern Memorial Hospital
Editor-in-Chief, JAMA Cardiology

No Relationships to Disclose

## **3DTEE in Intraoperative Echo**

























Optimal	Limited suitable	inappropriate Har	
Pathology in segment 2	Pathology in segment 1 or 3	Leaflet perforation or cleft	
No calcification	<ul> <li>Slight calcification outside the grasping area</li> <li>Ring calcification</li> <li>Anuloplasty with ring</li> </ul>	Severe calcification	
Valve area >4cm²	Valve area >3 cm <sup>2</sup> & good leaflet mobility	Mitral stenosis (< 3cm², gradient >5mmHg)	
Length of the posterior leaflet > 10mm	Length of the posterior leaflet 7-10mm	Length of the posterior leaflet < 7mm	
Coaptation depth < 11mm	Coaptation depth >11mm		
Normal thickness and mobility of the leaflets	Restriction (Carpentier IIIB)	Rheumatic thickening and restriction (Carpentier IIIA)	
MR with prolaps Flail size < 15mm Flail gap < 10mm	Flail size > 15mm only with large mitral aulus and option for more than 1 clip	Barlows desease	

















































**LA view** 

LV view



CLINICAL RESEARCH Interventional Cardiology

## **Percutaneous Mitral Valve Interventions** in the Real World

Early and 1-Year Results From the ACCESS-EU, A Prospective, Multicenter, Nonrandomized Post-Approval Study of the MitraClip Therapy in Europe

Francesco Maisano, MD,\* Olaf Franzen, MD,† Stephan Baldus, MD,‡ Ulrich Schäfer, MD,§ Jörg Hausleiter, MD,|| Christian Butter, MD,¶ Gian Paolo Ussia, MD,#\*\* Horst Sievert, MD,†† Gert Richardt, MD,‡‡ Julian D. Widder, MD,§§ Tiziano Moccetti, MD,|||| Wolfgang Schillinger, MD¶¶

Milan, Italy; Copenhagen, Denmark; Hamburg, Munich, Berlin, Frankfurt, Bad Segeberg, Hannover, and Göttingen, Germany; Catania, Italy; and Lugano, Switzerland

J Am Coll Cardiol 2013;62:1052-61




#### **CLINICAL RESEARCH**

## **Percutaneous Mitral Valve Interventions** in the Real World

Early and 1-Year Results From the ACCESS-EU, A Prospective, Multicenter, Nonrandomized Post-Approval Study of the MitraClip Therapy in Europe

Francesco Maisano, MD,\* Olaf Franzen, MD,† Stephan Baldus, MD,‡ Ulrich Schäfer, MD,§ Jörg Hausleiter, MD,|| Christian Butter, MD,¶ Gian Paolo Ussia, MD,#\*\* Horst Sievert, MD,†† Gert Richardt, MD,‡‡ Julian D. Widder, MD,§§ Tiziano Moccetti, MD,|||| Wolfgang Schillinger, MD¶¶

Milan, Italy; Cope Göttingen, German





Degenerative MR: primary valve disease

Functional MR: primary myocardial disease




Primary mitral regurgitation

Secondary mitral regurgitation



# Primary mitral regurgitation Secondary mitral regurgitation





#### Secondary mitral regurgitation




**Guideline-directed medical** therapy for heart failure, including CRT

class I



 Patients with severe MR undergoing CABG or AVR

class lla



class IIb

 Patients with moderate MR undergoing CABG or AVR

class IIb







# Indications for transcatheter MV repair for severe secondary MR:





- Severe secondary MR
- Severely symptomatic
- Prohibited or high surgical risk
- Reasonable life expectancy

class IIb





#### **Prevalence of MR in Patients with LV Dysfunction**


		N	Prevalence MR
Yiu et al	Circulation 2000	128	63%
Grigioni et al	Circulation 2001	303	64%
Koelling et al	Am Heart J 2002	1436	49% *
Trichon et al	Am J Cardiol 2003	2057	56%
Robbins et al	Am J Cardiol 2003	221	59%
Cleland et al	N Engl J Med 2004	605	50% *
Grayburn et al	J Am Coll Cardiol 2005	336	77%
Bursi et al	Circulation 2005	303	50%
Acker et al	J Thorac CV Surg 2006	300	66%
Di Mauro et al	Ann Thorac Surg 2006	239	75%
Rossi et al	Heart 2011	1300	74%
Deja et al	Circulation 2012	599	63%
Onishi et al	Circ Heart Fail 2013	277	48% *

<sup>\*</sup>Patients with moderate to severe MR



Secondary mitral regurgitation can be repaired.

But should it be repaired?





#### **FOCUS ISSUE: STRUCTURAL HEART DISEASE**


**Clinical Research** 

#### Correction of Mitral Regurgitation in Nonresponders to Cardiac Resynchronization Therapy by MitraClip Improves Symptoms and Promotes Reverse Remodeling

Angelo Auricchio, MD, PhD,\* Wolfgang Schillinger, MD,† Sven Meyer, MD,‡ Francesco Maisano, MD,§ Rainer Hoffmann, MD,|| Gian Paolo Ussia, MD,¶ Giovanni B. Pedrazzini, MD,\* Jan van der Heyden, MD,# Simona Fratini, MD, P Catherine Klersy, MD, MSc,†† Jan Komtebedde, DVM,\* Olaf Franzen, MD,‡ on behalf of the PERMIT-CARE Investigators

Lugano, Switzerland; Göttingen, Hamburg, and Aachen, Germany; Milan, Catania, L'Aquila, and Pavia, Italy; and Nieuwegein, the Netherlands

J Am Coll Cardiol 2011;58:2183-9






#### Percutaneous Mitral Valve **Edge-to-Edge Repair**

In-Hospital Results and 1-Year Follow-Up of 628 Patients of the 2011-2012 Pilot European Sentinel Registry

Georg Nickenig, MD, PhD,\* Rodrigo Estevez-Loureiro, MD, PhD,† Olaf Franzen, MD,† Corrado Tamburino, MD, PhD,§








#### Percutaneous Mitral Valve Edge-to-Edge Repair

In-Hospital Results and 1-Year Follow-Up of 628 Patients of the 2011-2012 Pilot European Sentinel Registry

Georg Nickenig, MD, PhD,\* Rodrigo Estevez-Loureiro, MD, PhD,† Olaf Franzen, MD,‡ Corrado Tamburino, MD, PhD,§

Marc Vanderheyden, MD, || Thos Reidar Winter, MD, PhD, †† Robe Stefan Blankenberg, MD, §§ Mag Anna Sonia Petronio, MD, ## He Maria Giovanna Fiorino, MD, §§§ Salvatore Scandura, MD, § Farqa Francesco Maisano, MD, PhD, ‡‡ Björn Plicht, MD, || || || Robert Sc Transcatheter Valve Treatment European Society of Cardiology

J Am Coll Cardiol 2014




















Indications for transcatheter MV repair for severe primary MR:

- Chronic severe MR
- Severely symptomatic
- Prohibited surgical risk
- Reasonable life expectancy

class Ilb













Indications for MV surgery for severe primary MR:





Repair better than mitral valve replacement

class I






 Repair is preferred treatment when durable

class I







#### INTERVENTIONAL CARDIOLOGY AND SURGERY

#### Mitral repair best practice: proposed standards

B Bridgewater, T Hooper, C Munsch, S Hunter, U von Oppell, S Livesty, B Keogh, F Wells, M Patrick, J Kneeshaw, J Chambers, N Masani, S Ray

••••••••••••••••••••••••

Heart 2006;92:939-944

#### 19 criteria for best practice:

- Surgical training
- Intraoperative echocardiograph
- Volume thresholds
- Audit
- Cardiology and imaging

Surgeon: >25/yr Hospital: >50/yr

Operative mortality <1% 5 year reoperation <5%

Rigorous criteria



## Predictors of Mitral Valve Repair: Clinical and Surgeon Factors


Steven F. Bolling, MD, Shuang Li, MS, Sean M. O'Brien, PhD, J. Matthew Brennan, MD, Richard L. Prager, MD, and James S. Gammie, MD

Section of Cardiac Surgery, University of Michigan, Ann Arbor, Michigan; Duke Clinical Research Institute, Durham, North Carolina; and Division of Cardiac Surgery, University of Maryland, Baltimore, Maryland

Ann Thorac Surg 2010;90:1904-

28,507 patients 1,088 surgeons 639 hospitals

Mean rate of repair: 41%
Median number of MV operations: 5






## Predictors of Mitral Valve Repair: Clinical and Surgeon Factors

Steven F. Bolling, MD, Shuang Li, MS, Sean M. O'Brien, PhD, J. Matthew Brennan, MD, Richard L. Prager, MD, and James S. Gammie, MD

Section of Cardiac Surgery, University of Michigan, Ann Arbor, Michigan; Duke Clinical Research Institute, Durham, North Carolina; and Division of Cardiac Surgery, University of Maryland, Baltimore, Maryland

Ann Thorac Surg 2010;90:1904-12

28,507 patients 1,088 surgeons 639 hospitals







Damien J. LaPar, MD, MSc,<sup>a</sup> Gorav Ailawadi, MD,<sup>a</sup> James M. Isbell, MD, MSCI,<sup>a</sup> Ivan K. Crosby, MD,<sup>a</sup> John A. Kern, MD,<sup>a</sup> Jeffrey B. Rich, MD,<sup>b</sup> Alan M. Speir, MD,<sup>c</sup> and Irving L. Kron, MD,<sup>a</sup> Investigators for the Virginia Cardiac Surgery Quality Initiative




Damien J. LaPar, MD, MSc,<sup>a</sup> Gorav Ailawadi, MD,<sup>a</sup> James M. Isbell, MD, MSCI,<sup>a</sup> Ivan K. Crosby, MD,<sup>a</sup> John A. Kern, MD,<sup>a</sup> Jeffrey B. Rich, MD,<sup>b</sup> Alan M. Speir, MD,<sup>c</sup> and Irving L. Kron, MD,<sup>a</sup> Investigators for the Virginia Cardiac Surgery Quality Initiative



Damien J. LaPar, MD, MSc,<sup>a</sup> Gorav Ailawadi, MD,<sup>a</sup> James M. Isbell, MD, MSCI,<sup>a</sup> Ivan K. Crosby, MD,<sup>a</sup> John A. Kern, MD,<sup>a</sup> Jeffrey B. Rich, MD,<sup>b</sup> Alan M. Speir, MD,<sup>c</sup> and Irving L. Kron, MD,<sup>a</sup> Investigators for the Virginia Cardiac Surgery Quality Initiative



Damien J. LaPar, MD, MSc,<sup>a</sup> Gorav Ailawadi, MD,<sup>a</sup> James M. Isbell, MD, MSCI,<sup>a</sup> Ivan K. Crosby, MD,<sup>a</sup> John A. Kern, MD,<sup>a</sup> Jeffrey B. Rich, MD,<sup>b</sup> Alan M. Speir, MD,<sup>c</sup> and Irving L. Kron, MD,<sup>a</sup> Investigators for the Virginia Cardiac Surgery Quality Initiative





# Hospital volume, mitral repair rates, and mortality in mitral valve surgery in the elderly: An analysis of US hospitals treating Medicare fee-for-service patients

Christina M. Vassileva, MD,<sup>a</sup> Christian McNeely, BS,<sup>a</sup> John Spertus, MD,<sup>b</sup> Stephen Markwell, MA,<sup>a</sup> and Stephen Hazelrigg, MD<sup>a</sup>

J Thorac Cardiovasc Surg 2015;149:762-8

#### Medicare data 2000-2009 1239 hospitals performing MV surgery

Number of MV operations/year:

- 91% performed ≤40
- 51% performed ≤10
- 29% performed ≤5

Number of MV repairs/year:

- 94% performed ≤20
- 65% performed ≤5
- 23% performed ≤1



# Mitral Regurgitation Percutaneous Edge-to-Edge Repair

- Incomplete percutaneous repair with residual MR probably *inferior* to complete successful surgical repair
- Incomplete percutaneous repair probably equivalent to incomplete surgical repair with residual MR
- Incomplete percutaneous repair probably superior to mitral valve replacement



#### **EDITORIAL COMMENT**

## The Time Has Come to Define Centers of Excellence in Mitral Valve Repair

Robert O. Bonow, MD, MS, David H. Adams, MD

J Am Coll Cardiol 2016;67:499-501

## Centers of Excellence in Mitral Valve Repair *Criteria:*

- MV surgery volume requirement (center and surgeon)
- Expert periprocedural imaging capabilities
- Access to transcatheter technology
- Transparency regarding outcomes including: repair rates, mortality rates, stroke rates, repair durability



